Figure 1From: Retrospective comparison between a regular and a split-dose protocol of 5-fluorouracil, cisplatin, and mitoxantrone for the treatment of far advanced hepatocellular carcinoma Survival analysis of patients with advanced HCC treated by FMP. (A) Overall survival in the two treated groups and the untreated group of patients. (B) Overall survival in the two groups of patients (regular and split-dose) achieving disease control and progressive diseases.Back to article page